Find comprehensive information on Glioblastoma Multiforme (GBM) including ICD-10 codes, clinical documentation improvement (CDI) best practices, diagnosis, treatment, prognosis, and healthcare resources. This resource provides details on GBM staging, histology, molecular markers, and brain tumor coding for accurate medical recordkeeping. Learn about glioblastoma multiforme survival rates, clinical trials, and the latest research advancements for optimizing patient care.
Also known as
Malignant neoplasm of brain
Cancers originating in brain tissues.
Malignant neoplasms of meninges, brain
Covers cancers affecting brain and surrounding membranes.
Neoplasms
Broad category encompassing all types of abnormal growths.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Glioblastoma, confirmed?
Yes
Is it NOS or specified type?
No
Do NOT code as Glioblastoma. Review clinical documentation for alternative diagnosis.
When to use each related code
| Description |
|---|
| Aggressive brain tumor |
| Anaplastic Astrocytoma |
| Diffuse Astrocytoma |
Missing or inadequate documentation of histologic confirmation of GBM diagnosis impacting accurate coding (ICD-10 C71.0).
Lack of clear laterality documentation (right, left, bilateral) for GBM affecting proper ICD-10 coding and reimbursement.
Insufficient documentation explicitly stating Grade IV or malignant behavior of astrocytoma for accurate GBM coding.
Patient presents with clinical manifestations consistent with Glioblastoma Multiforme (GBM), a highly malignant primary brain tumor. Presenting symptoms include persistent headaches, seizures, cognitive decline, focal neurological deficits such as hemiparesis or aphasia, and increased intracranial pressure. Magnetic Resonance Imaging (MRI) with contrast reveals a heterogeneously enhancing lesion with central necrosis, characteristic of GBM, located within the (specify lobe location e.g., frontal lobe). Differential diagnosis includes anaplastic astrocytoma, brain metastasis, and abscess. Histopathological analysis following surgical resection confirmed the diagnosis of Glioblastoma, WHO Grade IV. Molecular profiling demonstrates (specify molecular markers e.g., IDH-wildtype, MGMT promoter methylation status). Treatment plan includes maximal safe surgical resection followed by concurrent chemoradiation with temozolomide, aligned with current standard of care guidelines. Patient will be monitored for treatment response and potential adverse effects such as myelosuppression, radiation necrosis, and neurocognitive decline. Prognosis for Glioblastoma remains poor, and palliative care options will be discussed with the patient and family. Referral to neuro-oncology, radiation oncology, and physical therapy is initiated. ICD-10 code C71.9, malignant neoplasm of brain, unspecified, is assigned pending further specification based on laterality and histological confirmation. CPT codes for surgical resection, radiation therapy, and chemotherapy administration will be documented upon completion of those procedures. Continued surveillance with serial MRI imaging is planned to assess treatment response and disease progression.